Rare Disease Day

#rarediseaseday is in 2 days!

At Mironid, we are committed to transforming the treatment landscape for patients with Autosomal Dominant Polycystic Kidney Disease and other rare kidney diseases through novel scientific approaches.

ADPKD is a rare genetic disorder characterized by the formation of multiple fluid-filled cysts in the kidneys. These cysts can lead to kidney enlargement, loss of function, and associated complications.

ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60.

Despite being one of the more prevalent rare diseases, ADPKD has limited treatment options. Mironid is working to change this, with the development of small molecule therapeutics for the treatment of ADPKD and other rare kidney diseases.

The Latest

Mironid Raises Awareness for PKD with 1,000 km Team ChallengeApril 14, 2026

At Mironid, we’re proud to support causes that make a meaningful difference. Last month, our team took part in the Polycystic Kidney Disease (PKD) Charity UK‘s ‘Spring into March’ challenge, raising awareness and supporting the [...]

Q&A with David Henderson, Head of BiologyMarch 19, 2026

ADPKD is a devastating disease that affects more than 12 million people worldwide. Over the past decade, there has been important progress in our understanding of the disease, with meaningful steps forward for both patients and clinicians. However, significant challenges remain. Tolerability [...]

Allosteric modulation of long-form PDE4 enzymes, a novel disease modifying treatment for Autosomal Dominant Polycystic Kidney DiseaseFebruary 18, 2026

Our Chief Scientific Officer, Adele Rowley, will be in London on 18 February for this year’s Ace Drug Discovery Summit, where she will be giving a presentation titled “Allosteric modulation of long-form PDE4 enzymes, a [...]